Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 23, Issue 8, 2011, Pages

  Kanazawa, M ^a   Watanabe, S ^a   Tana, C ^a   Komuro, H ^a   Aoki, M ^a   Fukudo, S ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colonic motility; Irritable bowel syndrome; Mosapride; Serotonin (5 hydroxytryptamine); Visceral perception

Indexed keywords

MOSAPRIDE CITRATE; PLACEBO; WATER; BENZAMIDE DERIVATIVE; MORPHOLINE DERIVATIVE; MOSAPRIDE; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, HUMAN;

ADULT; ARTICLE; BAROSTAT; CLINICAL ARTICLE; COLON MOTILITY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; INTESTINE DISTENSION; INTESTINE FUNCTION; IRRITABLE COLON; MALE; PAIN ASSESSMENT; PAIN THRESHOLD; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTOSIGMOID MOTILITY; RECTOSIGMOID SENSORIMOTOR FUNCTION; SENSORIMOTOR FUNCTION; SIGMOID; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE TONE; TREATMENT OUTCOME; ANIMAL; DRUG EFFECT; GASTROINTESTINAL MOTILITY; GENETICS; MANOMETRY; METABOLISM; NOCICEPTION; PATHOPHYSIOLOGY; PHYSIOLOGY; RECTUM;

ADULT; ANIMALS; BENZAMIDES; COLON, SIGMOID; FEMALE; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MANOMETRY; MORPHOLINES; PAIN PERCEPTION; RECEPTORS, SEROTONIN, 5-HT4; RECTUM; SEROTONIN 5-HT4 RECEPTOR AGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 79960391094     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01732.x     Document Type: Article

References (38)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
2. Kanazawa M, Palsson OS, Thiwan SI et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol 2008; 103: 2550-61.
3. Greenwood-van Meerveld B. Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. Neurogastroenterol Motil 2007; 19(Suppl. 2): 13-8.
4. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414.
5. Tonini M, Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig Dis 2006; 24: 59-69.
6. Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008; 68: 981-91.
7. Asakawa H, Hayashi I, Fukui T, Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003; 61: 175-82.
8. Liu Z, Sakakibara R, Odaka T et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005; 20: 680-6.
9. Ueno N, Inui A, Satoh Y. The effect of mosapride citrate on constipation in patients with diabetes. Diabetes Res Clin Pract 2010; 87: 27-32.
10. Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31.
11. Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 979-86.
12. Li Y, Nie Y, Xie J et al. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci 2007; 52: 2942-9.
13. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): 1143-7.
14. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402.
15. Shinozaki M, Kanazawa M, Sagami Y et al. Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. J Gastroenterol 2006; 41: 491-4.
16. Patrick DL, Drossman DA, Frederick IO et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11.
17. Kanazawa M, Drossman DA, Shinozaki M et al. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med 2007; 1: 6.
18. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70.
19. Spielberger CD, Gorsuch RL, Lushene R et al. Manual for State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press, 1983.
20. Whitehead WE, Delvaux M, The Working Team of Glaxo-Wellcome Research, UK. Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract.. Dig Dis Sci 1997; 42: 223-41.
21. Bell AM, Pemberton JH, Hanson RB, Zinsmeister AR. Variations in muscle tone of the human rectum: recordings with an electromechanical barostat. Am J Physiol 1991; 260: G17-25.
22. Kanazawa M, Endo M, Yamaguchi K et al. Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. Neurogastroenterol Motil 2005; 17: 705-13.
23. Mizuno T, Aoki M, Shimada Y et al. Gender difference in association between polymorphism of serotonin transporter gene regulatory region and anxiety. J Psychosom Res 2006; 60: 91-7.
24. Fukudo S, Kanazawa M, Mizuno T et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention. Neuroimage 2009; 47: 946-51.
25. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370-80.
26. Yoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 1993; 43: 1078-83.
27. Inui A, Yoshikawa T, Nagai R et al. Effects of mosapride citrate, a 5-HT4 receptor agonist, on colonic motility in conscious guinea pigs. Jpn J Pharmacol 2002; 90: 313-20.
28. Kanaizumi T, Nakano H, Matsui Y et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991; 41: 335-7.
29. Krevsky B, Malmud LS, Maurer AH et al. The effect of oral cisapride on colonic transit. Aliment Pharmacol Ther 1987; 1: 293-304.
30. Appel S, Kumle A, Meier R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin Pharmacol Ther 1997; 62: 546-55.
31. Sloots CE, Poen AC, Kerstens R et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002; 16: 759-67.
32. Di Stefano M, Miceli E, Mazzocchi S et al. Effect of tegaserod on recto-sigmoid tonic and phasic activity in constipation-predominant irritable bowel syndrome. Am J Gastroenterol 2007; 102: 1720-6.
33. Cohen JE, Onyike CU, McElroy VL et al. Pharmacological characterization of an adenylyl cyclase-coupled 5-HT receptor in aplysia: comparison with mammalian 5-HT receptors. J Neurophysiol 2003; 89: 1440-55.
34. Liang LX, Zhang Q, Qian W, Hou XH. Antinociceptive property of tegaserod in a rat model of chronic visceral hypersensitivity. Chin J Dig Dis 2005; 6: 21-5.
35. 4 receptor agonist, on gastric distension-induced visceromotor response in conscious rats. J Pharmacol Sci 2011; 116: 47-53.
36. Sabate JM, Bouhassira D, Poupardin C et al. Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation. Neurogastroenterol Motil 2008; 20: 134-41.
37. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
38. Tsuchida Y, Hatao F, Fujisawa M et al. Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces anti-inflammatory actions via α7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut 2011; 60: 638-47.